Natco challenges Novartis’s second patent for cancer drug ribociclib in Delhi High Court
· livemint.com
Natco claims the new patent unlawfully extends Novartis’s market monopoly over the breast cancer medicine past 2027; Delhi High Court issues notices to all parties.
Krishna Yadav
Krishna Yadav is a Senior Correspondent at Mint, based in New Delhi, and part of the corporate bureau. He joined the newsroom as a trainee in 202...